Title:

Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds.

Running Head

Anti-SARS-CoV-2 RBD IgG evolution over time

Authors:

Maxence MEYER¹, M.D., Florentin CONSTANCIAS², Ph.D., Claudia Worth³, MB BChir., Anita MEYER⁴, M.D., Marion MULLER¹, M.D., Alexandre BOUSSUGE¹, M.D., Georges KALTENBACH¹, M.D., Ph.D., Elise SCHMITT¹, M.D., Ph.D., Saïd CHAYER⁵, PhD, HDR., , Ph.D, Aurélie VELAY^{6,7}, PharmD., Ph.D, Thomas VOGEL¹, M.D., Ph.D., Samira FAFI-KREMER^{6,7}, PharmD, Patrick KARCHER¹, M.D.

Affiliations:

¹Department of Geriatric, University Hospitals of Strasbourg, France

²ETH Zürich, Department of Health Sciences and Technology, Zurich, Switzerland

³Nuffield Department of Rheumatology, Orthopaedics and Musculoskeletal Sciences, University of Oxford

⁴COVID Vaccination Center, Offenburg, Germany

⁵Department of Clinical Research and Innovations, University Hospitals of Strasbourg, France

⁶Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

⁷INSERM, UMR_S1109, LabEx TRANSPLANTECH, Research Center for Immunology and Hematology, Faculty of Medicine, University Hospital Federation (FHU) OMICARE, Federation of Translational Medicine of Strasbourg (FMTS), University of Strasbourg, France

26 **Corresponding authors**

27 Maxence Meyer, MD : maxence.meyer@chru-strasbourg.fr

28 83 rue Himmerich,

29 67000 STRASBOURG

30

31 Manuscript word count: 764/750

32 Number of figure: 1

33 Number of supplementary table: 1

34 **Impact statement**

35 We certify that this work is novel clinical research.

36 This research adds to the literature descriptive data concerning the anti-RBD IgG immune
37 response in elderly people, supposedly protective, in the context of both natural infection
38 with COVID-19 as well as vaccination induced immunity. Notably, we present data for a
39 prolonged follow up period of up to 300 days. We are not aware of a description of geriatric
40 serology with BAU/ml, as currently recommended by WHO for universal comparison. We
41 are also not aware of the comparison of the values of these serologies observed in geriatrics
42 with theoretical protective thresholds.

43

44 **Key words**

45 SARS-CoV-2, serology, Anti-RBD IgG, Dynamics, Kinetics

46

47 **Funding source**

48 No specific funding was received for this work.

49

50 **ABSTRACT**

51 **INTRODUCTION**

52 The objectives of this study were to assess the dynamics of the SARS-CoV-2 anti-RBD IgG
53 response over time among older people after COVID-19 infection or vaccination and its
54 comparison with speculative levels of protection assumed by current data.

55 **METHODS**

56 From November 2020 to October 2021, we included geriatric patients with serological test
57 results for COVID-19.

58 We considered antibody titre thresholds thought to be high enough to protect against SARS-
59 CoV-2 infection: 141 BAU/ml for protection/vaccine efficacy > 89.3%.

60 Three cohorts are presented. A vaccine group (n=34) that received two BNT162b2/Comirnaty
61 injections 21 days apart, a group of natural COVID-19 infection (n=32) and a third group
62 who contracted COVID-19 less than 15 days after the first BNT162b2/Comirnaty injection
63 (n=17).

64 **RESULTS**

65 83 patients were included, the median age was 87 (81-91) years.

66 In the vaccine group at 1 month since the first vaccination, the median BAU/ml with IQR
67 was 620 (217-1874) with 87% of patients above the threshold of 141 BAU/ml. Seven months
68 after the first vaccination the BAU/ml was 30 (19-58) with 9.5% of patients above the
69 threshold of 141 BAU/ml.

70 In the natural COVID-19 infection group, at 1 month since the date of first symptom onset,
71 the median BAU/ml was 798 (325-1320) with 86.7% of patients above the threshold of 141
72 BAU/ml and fell to 88 (37-385) with 42.9% of patients above the threshold of 141 BAU/ml
73 at 2 months. The natural infection group was vaccinated three months after the infection. Five

74 months after the end of the vaccination cycle the BAU/ml was 2048 (471-4386) with 83.3%
75 of patients above the threshold of 141 BAU/ml.

76 **DISCUSSION**

77 On the humoral level, this supports the clinical results describing the decrease in vaccine
78 protection over time.

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99 INTRODUCTION

100 A better description of the kinetics of the anti-SARS-CoV-2 humoral response over time and
 101 its correlation with potential protection against COVID-19 among older people is necessary.
 102 SARS-CoV-2 anti-RBD (Receptor Binding Domain of the spike protein) IgG are correlated
 103 with neutralizing antibodies^{1,2} and are thought to be correlated with protection against
 104 COVID-19.^{2,3}
 105 The objectives of this study were to assess the dynamics of the SARS-CoV-2 anti-RBD IgG
 106 response over time among older people after COVID-19 infection or vaccination and its
 107 comparison with speculative levels of protection assumed by current data^{2,3}.

109 METHODS

110 The observational cohort study was approved by the institutional ethics board of the
 111 University Hospital of Strasbourg. Consent was collected for all patients.
 112 From November 2020 to October 2021, we included all geriatric hospital patients with
 113 serological test results for COVID-19 and a history of COVID-19 or COVID vaccination.
 114 Serum samples were tested using the SARS-CoV-2 IgG II Quant assay, detecting IgG
 115 antibodies directed against the spike RBD of SARS-CoV-2 with results expressed in Binding
 116 Antibody Units/ml (BAU/ml) as recommended by the WHO⁴. This allows interlaboratory
 117 comparison
 118 Based on data from previous studies, we considered 3 antibody titre thresholds thought to be
 119 high enough to protect against SARS-CoV-2 infection: 141 BAU/ml for protection/vaccine
 120 efficacy > 89.3% as suggested in the study by Dimeglio et al.³ and 165 BAU/ml and 506
 121 BAU/ml, respectively, for a protection/vaccine efficacy of 70% and 80% according to Feng
 122 et al.²

Three cohorts are presented. A vaccine group (n=34) that received two BNT162b2/Comirnaty injections 21 days apart, a group of natural COVID-19 infection (n=32) and a third group who contracted COVID-19 less than 15 days after the first BNT162b2/Comirnaty injection (n=17).

RESULTS

83 patients were included, including 60 women (72%). The median age and Charlson Comorbidity Index with Interquartile Range (IQR) was 87 (81-91) years and 7 (5-8.5).

Serological assessment and antibody titers

The results in the different groups as a function of time are shown in Figure 1 and Table S1.

In the vaccine group at 1 month since the first vaccination, the median BAU/ml with IQR was 620 (217-1874) with 87% of patients above the threshold of 141 BAU/ml. At 2 months since the first vaccination the BAU/ml was 526 (182-945) with 75% of patients above the threshold of 141 BAU/ml. Seven months after the first vaccination the BAU/ml was 30 (19-58) with 9.5% of patients above the threshold of 141 BAU/ml.

In the natural COVID-19 infection group, at 1 month since the date of first symptom onset, the median BAU/ml was 798 (325-1320) with 86.7% of patients above the threshold of 141 BAU/ml and fell to 88 (37-385) with 42.9% of patients above the threshold of 141 BAU/ml at 2 months. At three months the BAU/ml was 56 (29-203) with 33.3% of patients above the threshold of 141 BAU/ml. The natural infection group was vaccinated three months after the infection. Five months after the end of the vaccination cycle the BAU/ml was 2048 (471-4386) with 83.3% of patients above the threshold of 141 BAU/ml.

In the group who contracted COVID-19 less than 15 days after the first BNT162b2/Comirnaty injection, at 1 month from the first injection, the median BAU/ml was 463 (234-914) with 82.4% of patients above the threshold of 141 BAU/ml. At two months the BAU/ml was 484 (208-1167) with 85.7% of patients above the threshold of 141 BAU/ml. They received their second dose at three months. 4.5 months after the second dose the BAU/ml was 898 (437-2824) with 90.9% of patients above the threshold of 141 BAU/ml.

DISCUSSION

Seven months after the first vaccination in COVID-naïve patients, the RBD antibody titer decreases with a median BAU/ml of 30 and only 9.5% of patients above the theoretical protective threshold of 141 BAU/ml. A drop by a factor of 20 compared to the peak values which is consistent with the literature⁵. In COVID-19 patients, a median 56 BAU/ml is observed at three months with 33.3% of patients above the threshold of 141 BAU/ml. However COVID-19 patients, vaccinated at a distance from their infections present, five months post completion of the the vaccination schedule, antibody levels higher than peak levels observed at one month in those exposed to natural infection or standard vaccination alone.

On the humoral level, this supports the clinical results describing the decrease in vaccine protection over time⁶.

Limitations

Protective thresholds are currently very speculative.

Also even if the BAUs and the thresholds were to become clearer, these thresholds could change over time as the variants evolve and the humoral avidity could decrease in addition to the indisputable humoral decrease.

Sample size is limited.

173 **Acknowledgements:**

174 Conflict of Interest: The authors do not have any conflicts of interest.

175 Author contributions: All authors made substantial contributions to this article

176 The sponsor was Strasbourg University Hospital. The sponsor had no role on the design,
177 methods, subject recruitment, data collections, analysis and preparation of the paper.

178

179

180

References

1. Resman Rus K, Korva M, Knap N, Avšič Županc T, Poljak M. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay. *Journal of Clinical Virology*. 2021;139:104820. doi:10.1016/j.jcv.2021.104820
2. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med*. Published online September 29, 2021. doi:10.1038/s41591-021-01540-1
3. Dimeglio C, Herin F, Martin-Blondel G, Miedougé M, Izopet J. Antibody titers and protection against a SARS-CoV-2 infection. *Journal of Infection*. Published online September 2021:S0163445321004837. doi:10.1016/j.jinf.2021.09.013
4. Kristiansen PA, Page M, Bernasconi V, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. *The Lancet*. 2021;397(10282):1347-1348. doi:10.1016/S0140-6736(21)00527-4
5. Collier A ris Y, Yu J, McMahan K, et al. Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. *N Engl J Med*. Published online October 15, 2021:NEJMc2115596. doi:10.1056/NEJMc2115596
6. Goldberg Y, Mandel M, Bar-On YM, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. *N Engl J Med*. Published online October 27, 2021:NEJMoA2114228. doi:10.1056/NEJMoA2114228

Figure legends

Figure 1. Kinetics of anti-SARS-CoV-2 RBD IgG and theoretical protection against COVID-19 among older adults

Panel A: Evolution of humoral response (Anti-RBD IgG BAU/ml) over time.

Time axis reflects days since symptom onset (Natural COVID) or after BNT162b2 vaccine first injection (Vaccine group and Group who contracted COVID-19 less than 15 days after the first BNT162b2/Comirnaty injection).

Arrows in the x axis represent 2 BNT162b2/Comirnaty injections 21 days apart (Natural COVID) or the second BNT162b2/Comirnaty injection (Group who contracted COVID-19 less than 15 days after the first BNT162b2/Comirnaty injection)

Boxplots display Anti-RBD IgG BAU distribution at 1, 2, 3 months or during the post period (first quartile, median, third quartile and whiskers represent 1.5 times the interquartile range from the first and third quartiles).

Confidence interval of the mean (0.95 level) was estimated for each group using loess method to describe the dynamics of the humoral response during the first months.

Significant differences between periods were estimated within each group using pairwise non-parametric Kruskal-Wallis tests. Holm-adjusted p values indicate significant differences.

Horizontal dashed lines represent theoretical threshold of protection against COVID-19 as suggested by *Dimiglio et al.* (141 BAU/ml for protection/vaccine efficacy > 89.3%) and by *Feng et al.* (165 BAU/ml and 506 BAU/ml for protection/vaccine efficacy of 70% and 80%).

Panel B: Percentage of patients with theoretical protection against COVID-19=percentage of patients with Anti-RBD IgG titers above a protective threshold for each group, periods and different theoretical thresholds as defined in panel A.

231 **Supplementary Table legends**

232 Supplementary Table S1. Antibody titers and theoretical protection against COVID-19

233 among older adults

234

A

B

Table S1. Antibody titers and theoretical protection against COVID-19 among older adults

	Serology at 1 month	Serology at 2 months	Serology at 3 months		Remote serology
Vaccine group = 2 BNT162b2/Comirnaty injections 21 days apart N=34 Days since first vaccination Anti-RBD IgG BAU/ml Theoretical protection = Percentage of patients with Anti RBD IgG titers above the following threshold Cut-off Anti RBP Total =141 BAU/ml for protection against SARS-CoV 2> 89.3% according to Dimiglio et al. Cut-off Anti RBD IgG=165 BAU/ml for vaccine efficacy of 70% according to Feng et al. Cut-off Anti RBD IgG=506 BAU/ml for vaccine efficacy of 80% according to Feng et al.	N=23 38 (33,5-40,5) 620 (217-1874) 87,0 87,0 60,9	N=20 62 (60,75-64) 526 (182-945) 75,0 75,0 50,0	N=0 		N=21 218 (199-224) 30 (19-58) 9,5 9,5 0
Natural COVID group N=32 Days since first symptom onset (DSO) Days since the second vaccination following COVID infection Anti-RBD IgG BAU/ml Theoretical protection = Percentage of patients with Anti RBD IgG titers above the threshold Cut-off Anti RBP Total =141 BAU/ml for protection against SARS-CoV 2> 89.3% according to Dimiglio et al. Cut-off Anti RBD IgG=165 BAU/ml for vaccine efficacy of 70% according to Feng et al. Cut-off Anti RBD IgG=506 BAU/ml for vaccine efficacy of 80% according to Feng et al.	N=15 27 (26,5-29) 798 (325-1320) 86,7 86,7 60	N=14 68 (65-74) 88 (37-385) 42,9 42,9 21,4	N=15 91 (90-98) 56 (29-203) 33,3 33,3 0	2 BNT162b2/Comirnaty injections 21 days apart	N=6 293 (288-298) 144 (115-182) 2048 (471-4386) 83,3 83,3 66,7
Group who contracted COVID-19 less than 15 days after the first BNT162b2/Comirnaty injection N=17 Days since first vaccination Days since the second vaccination Anti-RBD IgG BAU/ml Theoretical protection = Percentage of patients with Anti RBD IgG titers above the threshold Cut-off Anti RBP Total =141 BAU/ml for protection against SARS-CoV 2> 89.3% according to Dimiglio et al. Cut-off Anti RBD IgG=165 BAU/ml for vaccine efficacy of 70% according to Feng et al. Cut-off Anti RBD IgG=506 BAU/ml for vaccine efficacy of 80% according to Feng et al.	N=17 29 (28-30) 463 (234-914) 82,4 82,4 35,3	N=14 69 (64-73) 484 (208-1167) 85,7 85,7 50	N=0 	Second BNT162b2/Comirnaty injection	N=11 260 (251,5-275,5) 138 (131-160) 898 (437-2824) 90,9 81,8 72,7

The data are medians (with interquartile range) for the study of Anti-RBD IgG titers and for the temporal expression of the parameter studied. The data are effective for description of sample size. The data are percentages for the expression of theoretical protection of patients with antibody titer above the suggested threshold.